pacritinib
Selected indexed studies
- Pacritinib. (, 2012) [PMID:38471026]
- Pacritinib. (, 2006) [PMID:35877951]
- Pacritinib for the treatment of patients with myelofibrosis and thrombocytopenia. (Expert Rev Hematol, 2022) [PMID:35983661]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Pacritinib. (2012) pubmed
- Pacritinib. (2006) pubmed
- Pacritinib for the treatment of patients with myelofibrosis and thrombocytopenia. (2022) pubmed
- Pacritinib: First Approval. (2022) pubmed
- Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial. (2018) pubmed
- Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial. (2017) pubmed
- Pacritinib for myelofibrosis in adults with thrombocytopenia. (2022) pubmed
- Pacritinib to treat myelofibrosis patients with thrombocytopenia. (2018) pubmed
- Pacritinib prevents inflammation-driven myelofibrosis-like phenotype in a miR-146a(-/-) murine model. (2024) pubmed
- Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management. (2023) pubmed